{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:14:05Z","timestamp":1785521645009,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":116,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-47351-7","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:55:00Z","timestamp":1775199300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world associations of pathological complete response and survival with neoadjuvant pembrolizumab in early TNBC: a Turkish Oncology Group study"],"prefix":"10.1038","volume":"16","author":[{"given":"Harun","family":"Mu\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdem","family":"S\u00fcnger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O\u011fuzcan","family":"\u00d6zkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha Koray","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahad\u0131r","family":"K\u00f6yl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaan","family":"Helvac\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Kemal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Sel\u00e7ukbiricik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl","family":"Ba\u015faran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ba\u015fak Oyan","family":"Ulu\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer Fatih","family":"\u00d6lmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhan","family":"G\u00f6kmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Bilici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"47351_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.32604\/or.2023.028525","volume":"31","author":"LS Popovic","year":"2023","unstructured":"Popovic, L. S. et al. Targeting triple-negative breast cancer: A clinical perspective. Oncol. Res. 31, 221\u2013238. https:\/\/doi.org\/10.32604\/or.2023.028525 (2023).","journal-title":"Oncol. Res."},{"key":"47351_CR2","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"KA Won","year":"2020","unstructured":"Won, K. A. & Spruck, C. Triple\u2011negative breast cancer therapy: Current and future perspectives (review). Int. J. Oncol. 57, 1245\u20131261. https:\/\/doi.org\/10.3892\/ijo.2020.5135 (2020).","journal-title":"Int. J. Oncol."},{"key":"47351_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI J. Natl. Cancer Inst. 106, dju055. https:\/\/doi.org\/10.1093\/jnci\/dju055 (2014).","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"47351_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar, W. J. et al. Breast cancer, version 3. 2024, NCCN clinical practice guidelines in oncology. J. National Comp. Cancer Network 22, 331\u2013357 (2024).","journal-title":"J. National Comp. Cancer Network"},{"key":"47351_CR5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","volume":"30","author":"HJ Burstein","year":"2019","unstructured":"Burstein, H. J. et al. Estimating the benefits of therapy for early-stage breast cancer: The St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann. Oncol. 30, 1541\u20131557. https:\/\/doi.org\/10.1093\/annonc\/mdz235 (2019).","journal-title":"Ann. Oncol."},{"key":"47351_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211059587","volume":"13","author":"M Gion","year":"2021","unstructured":"Gion, M. et al. Surrogate endpoints for early-stage breast cancer: A review of the state of the art, controversies, and future prospects. Ther. Adv. Med. Oncol. 13, 17588359211059588. https:\/\/doi.org\/10.1177\/17588359211059587 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"47351_CR7","volume":"375","author":"F Conforti","year":"2021","unstructured":"Conforti, F. et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: Systematic review and meta-analysis. BMJ 375, e06638 (2021).","journal-title":"BMJ"},{"key":"47351_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193389","volume":"16","author":"E Karci","year":"2024","unstructured":"Karci, E. et al. Neoadjuvant pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer: A nationwide retrospective Turkish Oncology Group study. Cancers 16, 3389. https:\/\/doi.org\/10.3390\/cancers16193389 (2024).","journal-title":"Cancers"},{"key":"47351_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1207948","volume":"13","author":"N Ivanovic","year":"2023","unstructured":"Ivanovic, N. et al. Changing the role of pCR in breast cancer treatment - An unjustifiable interpretation of a good prognostic factor as a \u201cfactor for a good prognosis\u201d. Front. Oncol. 13, 1207948. https:\/\/doi.org\/10.3389\/fonc.2023.1207948 (2023).","journal-title":"Front. Oncol."},{"key":"47351_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549 (2020).","journal-title":"N. Engl. J. Med."},{"key":"47351_CR11","unstructured":"Nanda, R. et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. Proceedings of the American Society of Clinical Oncology. (2017)."},{"key":"47351_CR12","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf, E. A. et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 trial. Lancet 396, 1090\u20131100. https:\/\/doi.org\/10.1016\/S0140-6736(20)31953-X (2020).","journal-title":"Lancet"},{"key":"47351_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100061","author":"L Rached","year":"2024","unstructured":"Rached, L. et al. Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer. ESMO Real World Data Digit. Oncol. https:\/\/doi.org\/10.1016\/j.esmorw.2024.100061 (2024).","journal-title":"ESMO Real World Data Digit. Oncol."},{"key":"47351_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.37349\/etat.2024.00215","volume":"5","author":"P De Santis","year":"2024","unstructured":"De Santis, P. et al. Early-stage triple negative breast cancer: The therapeutic role of immunotherapy and the prognostic value of pathological complete response. Explor. Target. Antitumor Ther. 5, 232\u2013250. https:\/\/doi.org\/10.37349\/etat.2024.00215 (2024).","journal-title":"Explor. Target. Antitumor Ther."},{"key":"47351_CR15","doi-asserted-by":"publisher","DOI":"10.21037\/cco-24-54","volume":"13","author":"M Antonini","year":"2024","unstructured":"Antonini, M. et al. Real-world evidence of survival outcomes in breast cancer subtypes after neoadjuvant chemotherapy in a Brazilian reference center. Chin. Clin. Oncol. 13, 65. https:\/\/doi.org\/10.21037\/cco-24-54 (2024).","journal-title":"Chin. Clin. Oncol."},{"key":"47351_CR16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17081-7","author":"LM Perry","year":"2025","unstructured":"Perry, L. M. et al. Predictors of pathologic complete response with neoadjuvant chemo-immunotherapy in early-stage triple-negative breast cancer. Ann. Surg. Oncol. https:\/\/doi.org\/10.1245\/s10434-025-17081-7 (2025).","journal-title":"Ann. Surg. Oncol."},{"key":"47351_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1570394","volume":"16","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. Pathological complete response and prognostic predictive factors of neoadjuvant chemoimmunotherapy in early stage triple-negative breast cancer. Front. Immunol. 16, 1570394. https:\/\/doi.org\/10.3389\/fimmu.2025.1570394 (2025).","journal-title":"Front. Immunol."},{"key":"47351_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384, 164\u2013172. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8 (2014).","journal-title":"Lancet"},{"key":"47351_CR19","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman, R. E. et al. Real-world evidence \u2014 What is it and what can it tell us?. N. Engl. J. Med. 375, 2293\u20132297. https:\/\/doi.org\/10.1056\/NEJMsb1609216 (2016).","journal-title":"N. Engl. J. Med."},{"key":"47351_CR20","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/CAD.0000000000001196","volume":"33","author":"W Feng","year":"2022","unstructured":"Feng, W. et al. A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer. Anticancer Drugs 33, e52\u2013e60. https:\/\/doi.org\/10.1097\/CAD.0000000000001196 (2022).","journal-title":"Anticancer Drugs"},{"key":"47351_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.breast.2022.04.006","volume":"64","author":"N Pathak","year":"2022","unstructured":"Pathak, N. et al. Moment of truth-adding carboplatin to neoadjuvant\/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level meta-analysis. Breast 64, 7\u201318. https:\/\/doi.org\/10.1016\/j.breast.2022.04.006 (2022).","journal-title":"Breast"},{"key":"47351_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/s1470-2045(14)70160-3","volume":"15","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz, G. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol. 15, 747\u2013756. https:\/\/doi.org\/10.1016\/s1470-2045(14)70160-3 (2014).","journal-title":"Lancet Oncol."},{"key":"47351_CR23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl, S. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): A randomised, phase 3 trial. Lancet Oncol. 19, 497\u2013509. https:\/\/doi.org\/10.1016\/S1470-2045(18)30111-6 (2018).","journal-title":"Lancet Oncol."},{"key":"47351_CR24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nri.2017.107","volume":"17","author":"Y Bordon","year":"2017","unstructured":"Bordon, Y. Regulatory ILCs don\u2019t rely on FOXP3. Nat. Rev. Immunol. 17, 594\u2013594. https:\/\/doi.org\/10.1038\/nri.2017.107 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"47351_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.immuni.2008.06.010","volume":"29","author":"I Puga","year":"2008","unstructured":"Puga, I., Rao, A. & Macian, F. Targeted cleavage of signaling proteins by caspase 3 inhibits T cell receptor signaling in anergic T cells. Immunity 29, 193\u2013204. https:\/\/doi.org\/10.1016\/j.immuni.2008.06.010 (2008).","journal-title":"Immunity"},{"key":"47351_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","volume":"56","author":"F Ghiringhelli","year":"2007","unstructured":"Ghiringhelli, F. et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.. Cancer Immunol. Immunother. 56, 641\u2013648. https:\/\/doi.org\/10.1007\/s00262-006-0225-8 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"47351_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw199","author":"EE Parkes","year":"2016","unstructured":"Parkes, E. E. et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer.. J. Natl. Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djw199 (2016).","journal-title":"J. Natl. Cancer Inst."},{"key":"47351_CR28","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano, J. A. et al. Weekly paclitaxel in the adjuvant treatment of breast cancer.. N. Engl. J. Med. 358, 1663\u20131671. https:\/\/doi.org\/10.1056\/NEJMoa0707056 (2008).","journal-title":"N. Engl. J. Med."},{"key":"47351_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl, S. et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 35, 159\u2013182. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016 (2024).","journal-title":"Ann. Oncol."},{"key":"47351_CR30","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1245\/s10434-025-17081-7","volume":"32","author":"LM Perry","year":"2025","unstructured":"Perry, L. M. et al. Predictors of pathologic complete response with neoadjuvant chemo-immunotherapy in early-stage triple-negative breast cancer.. Ann. Surg. Oncol. 32, 3991\u20134001 (2025).","journal-title":"Ann. Surg. Oncol."},{"key":"47351_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/go-24-00340","author":"A Mattar","year":"2025","unstructured":"Mattar, A. et al. Overall Survival and Economic Impact of Triple-Negative Breast Cancer in Brazilian Public Health Care: A Real-World Study. JCO Global Oncology https:\/\/doi.org\/10.1200\/go-24-00340 (2025).","journal-title":"JCO Global Oncology"},{"key":"47351_CR32","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1245\/s10434-024-16390-7","volume":"32","author":"C Connors","year":"2025","unstructured":"Connors, C. et al. Real-world outcomes with the KEYNOTE-522 regimen in early-stage triple-negative breast cancer.. Ann. Surg. Oncol. 32, 912\u2013921. https:\/\/doi.org\/10.1245\/s10434-024-16390-7 (2025).","journal-title":"Ann. Surg. Oncol."},{"key":"47351_CR33","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","volume":"25","author":"AE Giuliano","year":"2018","unstructured":"Giuliano, A. E., Edge, S. B. & Hortobagyi, G. N. Eighth edition of the AJCC cancer staging manual: Breast cancer.. Ann. Surg. Oncol. 25, 1783\u20131785. https:\/\/doi.org\/10.1245\/s10434-018-6486-6 (2018).","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"47351_CR34","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"MEH Hammond","year":"2010","unstructured":"Hammond, M. E. H. et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28(4), 2784\u20132795 (2010).","journal-title":"J. Clin. Oncol."},{"key":"47351_CR35","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1200\/JCO.23.00435","volume":"41","author":"JK Litton","year":"2023","unstructured":"Litton, J. K. et al. Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP. J. Clin. Oncol. 41, 4433\u20134442. https:\/\/doi.org\/10.1200\/JCO.23.00435 (2023).","journal-title":"J. Clin. Oncol."},{"key":"47351_CR36","unstructured":"Administration, U. S. F. a. D. Guidance for Industry: Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer. (U.S. Department of Health and Human Services, Silver Spring, MD, 2014)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47351-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47351-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47351-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:04:39Z","timestamp":1785517479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47351-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47351"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47351-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Istanbul Medipol University (Decision No: 327, Date: 20.03.2025). The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients or their legal representatives.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23393"}}